Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HLA-DRB1 | P01911 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 5/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21109104 | 0.98 | CTSK (0.36) | HLA-DRB1CTSKCTSSCTSBCTSL | |
| SCHEMBL21109148 | 0.94 | HLA-DRB1 (0.39) | HLA-DRB1CTSKCTSSCTSBCTSL | |
| SCHEMBL21109323 | 0.92 | HLA-DRB1 (0.36) | HLA-DRB1CTSKCTSSCTSBCTSL | |
| SCHEMBL21109101 | 0.92 | CTSK (0.42) | CTSKCTSSCTSBCTSL | |
| SCHEMBL21109078 | 0.90 | ALDH1A1 (0.40) | HLA-DRB1CTSKCTSSCTSBCTSL | |
| SCHEMBL21110026 | 0.88 | ALDH1A1 (0.41) | HLA-DRB1CTSKCTSSCTSBCTSL | |
| SCHEMBL21109315 | 0.86 | CTSK (0.42) | HLA-DRB1CTSKCTSSCTSBCTSL | |
| SCHEMBL21109992 | 0.85 | HLA-DRB1 (0.39) | HLA-DRB1CTSKCTSSCTSBCTSL | |
| SCHEMBL21110025 | 0.85 | GAA (0.42) | CTSKCTSSCTSBCTSL | |
| SCHEMBL21109655 | 0.83 | HLA-DRB1 (0.44) | HLA-DRB1CTSKPSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590084-B2 | Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof | BLADE THERAPEUTICS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190194139-A1 | CYCLIC KETO-AMIDE COMPOUNDS AS CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF | BLADE THERAPEUTICS, INC. (US) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194139-A1 | CYCLIC KETO-AMIDE COMPOUNDS AS CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF | CAPN1, CAPN9, CAPN2 | HLA-DRB1 4722/4885CTSK 566/4885CTSS 905/4885 |
| US-10590084-B2 | Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof | CAPN1, CAPN9, CAPN2 | HLA-DRB1 4722/4885CTSK 566/4885CTSS 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.